Results 131 to 140 of about 15,200 (191)

Daratumumab-Based Regimen Significantly Induced Remission of Crystalline Light Chain Proximal Tubulopathy: A Case Report. [PDF]

Am J Case Rep
Zou X, Wang K, Zeng R.
europepmc   +1 more source

Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis. [PDF]

Front Immunol
Wang B, Chu Y, Zhang C, Guo S.
europepmc   +1 more source

Abordagem do Mieloma Múltiplo em Doentes Jovens - A propósito de um caso clínico [PDF]

, 2014
Inês Filipa Monteiro Cordeiro Ferro
core  

Daratumumab for CD20^-CD38⁺ Relapsed/Refractory Diffuse Large B-Cell Lymphoma. [PDF]

J Cell Mol Med
Hong Z, Hong Z, Ma Y, Yin Q, Liu M, Huang W, Zhou K, Li D, Li T, Zheng M.   +9 more
europepmc   +1 more source

CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells. [PDF]

Sci Rep
Pape LJ, Gebhardt AJ, Dannenberg M, Risch H, Duttmann A, Weisel K, Hambach J, Koch-Nolte F, Bannas P.   +8 more
europepmc   +1 more source

Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. [PDF]

Pharmaceutics
Osuna-Gómez R, López-Pardo J, Mulet M, Nomdedéu J, Cantó E, Ortin R, Cayuela ÁS, Ortiz MÀ, Guinart-Cuadra A, Vidal S.   +9 more
europepmc   +1 more source

Efficacy and Safety of Newly Diagnosed Multiple Myeloma Combination Therapies: A Systematic Review Integrating Network Meta-Analysis and Real-World Vigilance Study. [PDF]

Pharmaceuticals (Basel)
Liu Y, Zhang Y, Yang W, Du H, Sun S, Li Z, Zong D.   +6 more
europepmc   +1 more source

CD38 as an immunotherapeutic target in multiple myeloma [PDF]

, 2018
Boccadoro, M., Bonello, F., Cerrato, C., D'Agostino, M., Gay, F., Moscvin, M.   +5 more
core   +1 more source

CD38-targeted therapy with Daratumumab in clinical lung transplantation: A single-center experience. [PDF]

JHLT Open
Hillebrand C, Maggioni G, Auner S, Boehm PM, Koren D, Kovacs Z, Schwarz S, Fischer G, Müller A, Kain R, Hoetzenecker K, Aigner C, Calabrese F, Jaksch P, Benazzo A.   +14 more
europepmc   +1 more source